Boehringer Ingelheim Pharmaceuticals, Inc.

Eisai R&d Management Co., Ltd.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Ming-Hong Hao

John JianShi Wang

Derek Cogan

Dominic J Reynolds

Alan David Swinamer

Sudeep Prajapati

Kevin Chungeng Qian

Daniel R Goldberg

Atsushi Endo

Sanxing Sun

Tina Marie Morwick

Zhaoming Xiong

Peter Allen Nemoto

Takashi Satoh

Victor Marc Kamhi

Ronald A Aungst, Jr

Anand Selvaraj

Eugene R Hickey

Weimin Liu

Pier Francesco Cirillo

Hyeong-wook Choi

Matthew Russell Netherton

Dae-Shik Kim

Frank Fang

Kuan-Chun Huang

Xingfeng Bao

Neil Moss

Guo Zhu Zheng

Hidenori Takahashi

Lifen Wu

Charles Lawrence Cywin

Abdelhakim Hammach

Ronald John Sorcek

Zhidong Chen

Donghong Amy Gao

Daniel Richard Marshall

Jiang-Ping Wu

Roman Wolfgang Fleck

Jonathan Emillian Emeigh

Mark G Bock

Susanta Samajdar

Ping Zhu

Peter G Smith

Craig Andrew Miller

Asitha Abeywardane

Chuk Chui Man

Steven John Taylor

Mark Stephen Ralph

Manav Korpal

Vijay Kumar Nyavanandi

Xiaoling Puyang

Amy L Davis

Yoshihiko Kotake

Steffen Breitfelder

Gregg F Keaney

Christopher Ronald Sarko

Andrew Cook

Heather Tye

Stephane De Lombaert

Ho Yin Lo

Kazunobu Kira

Michel Jose Emmanuel

Pui Leng Loke

Marta Nevalainen

Parcharee Tivitmahaisoon

Can Mao

John David Ginn

Brian Nicholas Cook

Arani Chanda

Norio Murai

Peter Gerard Smith

Jin Mi Kim

Kristen Sanders

George Moniz

Jason T Lowe

Xin Guo

Darren DiSalvo

Baudouin Gerard

Xiang Liu

James Palacino

Gregory Paul Roth

Rajiv Sharma

Kenshi Yoshida

Satoshi Nagao

Shelby Ellery

Masayuki Miyano

Kenzo Arai

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Erick Richard Young

Lisa A Marcaurelle

Ho-Yin Lo

Morgan Welzel O'shea

Tuoping Luo

Alan D Swinamer

Dominic Reynolds

Provided herein are methods for the treatment of bladder cancer.

Methods for the treatment of bladder cancer

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.

Crystalline FGFR4 inhibitor compound and uses thereof

Provided herein are compounds useful for the treatment of cancer.

Compounds for the treatment of cancer

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Pyrimidine FGFR4 inhibitors

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-&#x3b1; protein.

Tetrasubstituted alkene compounds and their use

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

Benzimidazolone chymase inhibitors

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.  Also disclosed are pharmaceutical compositions, methods of using and making the same.

Chymase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salt thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Benzimidazole inhibitors of leukotriene production

Growing community of inventors

Ridgefield, CT, United States of America

Ming-Hong Hao